DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20204506

Acute ST-elevation myocardial infraction after use of oral sumatriptan: a rare presentation

Indira Sahu, Manish Ruhela, Rakesh Kumar Ola

Abstract


Sumatriptan is an agonist of 5-hydroxytryptamine type-1 (5HT1) receptors that is widely used as a migraine abortant; however, there have been studies showing angina, coronary vasospasm, and even myocardial infraction in patients with predisposing cardiac risk factors. We present the case of a female patient with no cardiovascular risk factor who developed ST-elevation myocardial infraction 30 minutes after ingesting oral sumatriptan for her migraine.


Keywords


Sumatriptan, Migraine, Myocardial infraction

Full Text:

PDF

References


Cady RK, Wendt JK, Kirchner JR. The treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-5.

The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-21.

Stricker BH. Coronary vasospasm and sumatriptan. BMJ. 1002;305:118.

Davies MB, Krishnan A. Atrial fibrillation induced by sumatriptan. Cephalalgia. 2005;25:924-5.

O’Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infraction. Neurol. 1995;45:2274-6.

Ottervanger JP, Pealman HJ, Boxma GL. Transmural myocardial infraction with sumatriptan. Lancet. 1993;341:861-2.

Plosay JJ, O’Connell TX. Acute coronary vasospasm resulting from sumatriptan administration in a patient with Raynaud’s disease. Hosp Physician. 2002;38:51-4.

VanDenBrink MA, Reekers M, Bax WA. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98(1):25-30.

Mikhail GW, Airoldi F, Columbo A. Acute myocardial infraction following the use of antimigraine therapy. J Invasive Cardiol. 2004;16(10):602-3.

Inman W, Kubota K. Cardiorespiratory distress after sumatriptan given by ingestion. BMJ. 1992;305(6855):713-4.

Laine K, Raasalkka T. Fatal cardiac arrhythmia after oral sumatriptan. Headache. 1999;39(7):511-2.

Villalon CM, Centurion D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved in therapeutic implications. Arch Pharmacol. 2007;376(1-2):45-63.

McIntyre PD, Bhargava B, Hogg KJ. The effect of subcutaneous sumatriptan on the systemic, pulmonary and coronary circulation. Circulation. 1993;87:401-5.